Comparative Pharmacology
Head-to-head clinical analysis: BUPIVACAINE HYDROCHLORIDE KIT versus PARACAINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUPIVACAINE HYDROCHLORIDE KIT versus PARACAINE.
BUPIVACAINE HYDROCHLORIDE KIT vs PARACAINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bupivacaine is an amide-type local anesthetic that blocks sodium channels in neuronal cell membranes, inhibiting the propagation of action potentials and thus producing local anesthesia and analgesia.
Local anesthetic that reversibly blocks sodium channels in neuronal membranes, inhibiting nerve impulse conduction.
0.25% to 0.5% solution administered via epidural, peripheral nerve block, or local infiltration; maximum single dose 175 mg (without epinephrine) or 225 mg (with epinephrine 1:200,000); may repeat every 3-6 hours as needed, not to exceed 400 mg in 24 hours.
10-20 mg orally every 4-6 hours as needed; maximum 80 mg/day.
None Documented
None Documented
Clinical Note
moderateProparacaine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Proparacaine is combined with Fluticasone propionate."
Clinical Note
moderateProparacaine + Clemastine
"The risk or severity of adverse effects can be increased when Proparacaine is combined with Clemastine."
Clinical Note
moderateProparacaine + Venlafaxine
"The risk or severity of adverse effects can be increased when Proparacaine is combined with Venlafaxine."
Clinical Note
moderateTerminal elimination half-life is 2.7 to 3.5 hours in adults, prolonged in neonates (8-14 hours) and patients with hepatic impairment. Clinically, this supports intermittent dosing or continuous infusion monitoring.
2.5 hours; prolonged to 8 hours in cirrhosis due to reduced hepatic metabolism
Primarily hepatic metabolism (approx. 95%) to metabolites (e.g., pipecoloxylidine, desbutylbupivacaine); less than 5% excreted unchanged in urine. Biliary/fecal elimination accounts for a minor fraction. Renal clearance of unchanged drug is about 2-6%.
Renal: 90% (70% unchanged, 20% as paracainol glucuronide); Biliary/Fecal: 10%
Category C
Category C
Local Anesthetic
Local Anesthetic
Proparacaine + Nefazodone
"The risk or severity of adverse effects can be increased when Proparacaine is combined with Nefazodone."